Humacyte (HUMA) Competitors $4.41 -0.01 (-0.23%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HUMA vs. EVLV, DSKE, BARK, SST, BODY, NAMS, CGON, KROS, WVE, and AKROShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Evolv Technologies (EVLV), Daseke (DSKE), BARK (BARK), System1 (SST), Beachbody (BODY), NewAmsterdam Pharma (NAMS), CG Oncology (CGON), Keros Therapeutics (KROS), Wave Life Sciences (WVE), and Akero Therapeutics (AKRO). Humacyte vs. Evolv Technologies Daseke BARK System1 Beachbody NewAmsterdam Pharma CG Oncology Keros Therapeutics Wave Life Sciences Akero Therapeutics Humacyte (NASDAQ:HUMA) and Evolv Technologies (NASDAQ:EVLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations. Which has more risk & volatility, HUMA or EVLV? Humacyte has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Evolv Technologies has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Does the MarketBeat Community favor HUMA or EVLV? Humacyte received 18 more outperform votes than Evolv Technologies when rated by MarketBeat users. However, 64.71% of users gave Evolv Technologies an outperform vote while only 63.04% of users gave Humacyte an outperform vote. CompanyUnderperformOutperformHumacyteOutperform Votes2963.04% Underperform Votes1736.96% Evolv TechnologiesOutperform Votes1164.71% Underperform Votes635.29% Is HUMA or EVLV more profitable? Humacyte has a net margin of 0.00% compared to Evolv Technologies' net margin of -21.42%. Evolv Technologies' return on equity of -28.57% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A -942.81% -93.82% Evolv Technologies -21.42%-28.57%-14.76% Do analysts recommend HUMA or EVLV? Humacyte presently has a consensus target price of $11.00, indicating a potential upside of 149.43%. Evolv Technologies has a consensus target price of $5.60, indicating a potential upside of 113.74%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Evolv Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Evolv Technologies 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media prefer HUMA or EVLV? In the previous week, Humacyte had 7 more articles in the media than Evolv Technologies. MarketBeat recorded 36 mentions for Humacyte and 29 mentions for Evolv Technologies. Evolv Technologies' average media sentiment score of 0.00 beat Humacyte's score of -0.09 indicating that Evolv Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 4 Positive mention(s) 16 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Evolv Technologies 1 Very Positive mention(s) 0 Positive mention(s) 26 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, HUMA or EVLV? Evolv Technologies has higher revenue and earnings than Humacyte. Evolv Technologies is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$1.57M353.53-$110.78M-$1.34-3.29Evolv Technologies$80.42M5.13-$106.25M-$0.14-18.71 Do insiders and institutionals hold more shares of HUMA or EVLV? 44.7% of Humacyte shares are owned by institutional investors. Comparatively, 66.7% of Evolv Technologies shares are owned by institutional investors. 11.2% of Humacyte shares are owned by company insiders. Comparatively, 11.2% of Evolv Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryHumacyte beats Evolv Technologies on 11 of the 19 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$555.04M$2.95B$5.06B$8.89BDividend YieldN/A1.90%4.97%4.06%P/E Ratio-3.2917.8689.0213.30Price / Sales353.53222.321,207.2881.01Price / CashN/A160.0839.1736.03Price / Book33.924.906.085.74Net Income-$110.78M-$41.63M$119.07M$225.93M7 Day Performance-8.88%-4.73%-1.84%-1.32%1 Month Performance-17.42%-6.53%-3.65%0.60%1 Year Performance80.74%25.63%31.62%26.23% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte2.8803 of 5 stars$4.41-0.2%$11.00+149.4%+71.6%$555.04M$1.57M-3.29150Insider TradeEVLVEvolv Technologies1.539 of 5 stars$2.62-4.0%$5.60+113.7%-37.3%$430.11M$80.42M0.00170DSKEDasekeN/A$8.29-0.1%$8.30+0.1%+88.4%$391.29M$1.57B-14.054,182BARKBARK1.1919 of 5 stars$1.63+2.5%$1.90+16.9%+103.2%$274.85M$490.18M0.00640SSTSystem12.2739 of 5 stars$0.96-1.0%$2.00+108.6%-17.3%$89.15M$401.97M0.00320BODYBeachbodyN/A$8.14-2.0%N/A+5,426.1%$50.88M$692.20M-0.381,021Gap UpNAMSNewAmsterdam Pharma2.936 of 5 stars$20.01-15.5%$33.80+68.9%+110.6%$2.19B$14.09M0.0057Insider TradeNews CoverageGap DownHigh Trading VolumeCGONCG Oncology3.1626 of 5 stars$32.24-1.7%$63.88+98.1%N/A$2.18B$684,000.000.0061Short Interest ↓Analyst RevisionKROSKeros Therapeutics3.4913 of 5 stars$54.14+1.0%$88.89+64.2%+80.5%$2.17B$150,000.000.00100WVEWave Life Sciences4.8489 of 5 stars$14.26+0.4%$21.89+53.5%+174.2%$2.17B$113.31M0.00240Analyst RevisionAKROAkero Therapeutics4.0502 of 5 stars$30.64-1.3%$46.83+52.9%+83.8%$2.14BN/A-8.1730Analyst ForecastInsider Trade Related Companies and Tools Related Companies EVLV Competitors DSKE Competitors BARK Competitors SST Competitors BODY Competitors NAMS Competitors CGON Competitors KROS Competitors WVE Competitors AKRO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HUMA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
